Artificial Intelligence in Medicine Regulation: From Concept to Practice

Artificial intelligence in medicine regulation is moving from concept to practice at the European Medicines Agency (EMA). In a new page on its website, EMA says it and the European medicines regulatory network are making that transition. The shift mirrors how the pharmaceutical industry already uses AI at every step of the medicine lifecycle, from drug discovery to safety monitoring.

Artificial intelligence in medicine regulation: the timeline

The timeline starts with a joint EMA-HMA workshop in April 2021 and runs to a scientific article published in August 2026. EMA says the list is not complete. Earlier milestones include the first EMA qualification opinion on an AI-based methodology, issued by the CHMP in March 2025, and the common EMA-FDA principles for AI in medicine development, published in November 2025. The newest entries include the EMA AI Observatory report for 2025, published in June 2026.

The page says its concept of AI is in line with Regulation (EU) 2024/1689, the AI Act. It describes AI as computer systems that use data to generate predictions, recommendations, content or decisions, and notes that some AI systems adapt and improve their performance based on experience.

Ad

Why it matters

EMA expects AI to help achieve concrete, positive outcomes, including speeding up development of medicines, optimising clinical evidence and medicine quality, and delivering high-quality regulatory work. The page gives no dates or targets for them, so they read as direction rather than commitments. It names product quality and manufacturing efficiency among the areas where AI creates new opportunities. Syenza News has covered an EMA workshop on AI in GMP manufacturing for readers who want that side in detail.

Source: European Medicines Agency, “Artificial intelligence in medicine regulation: from concept to practice” (page first published 11 November 2026)